The CGT Catapult has shaped a consortium aimed toward advancing the expertise improvement and decreasing prices of cell and gene remedy manufacturing.
The Cell and Gene Remedy Catapult (CGT Catapult) has shaped a consortium of greater than 20 organizations aimed toward advancing the expertise improvement and decreasing prices of cell and gene remedy manufacturing.
In a June 8, 2021 press launch, CGT Catapult introduced the formation of the consortium, which can assess a number of course of analytical applied sciences (PAT) which are both new or routinely utilized in different industries. Via collaboration and sharing of knowledge, the consortium will act as a catalyst to speed up the event of the required information and understanding at lowered price and funding danger to every group.
“The business must make a large leap when it comes to analytical functionality and the dynamic use of knowledge to manage and enhance processes, product, and prices,” stated Matthew Durdy, CEO at CGT Catapult, within the press launch. “The approaching collectively of those leaders within the area is a vital first step in the direction of reaching this.”
“By sharing information and information, the consortium members will be capable to reap probably big advantages that might result in extra environment friendly processes on this important area,” added Nicholas Medcalf, deputy problem director—Medicines Manufacturing for Innovate UK, within the press launch. “The Cell and Gene Remedy Catapult—supported by Innovate UK—is demonstrating its incredible convening energy in harnessing these main business gamers for the larger good of UK enterprise and innovation.”
Supply: CGT Catapult